Disease-modifying therapies and Coronavirus disease
May 3, 2021Study investigating the severity of Coronavirus disease in People with Multiple Sclerosisread more
Study investigating the severity of Coronavirus disease in People with Multiple Sclerosisread more
International Progressive MS Alliance e-News - March 2021 In this issue: • Read about the recent call to action to prioritise research on symptoms that matter most to people affected…read more
Mavenclad (cladribine) reduces the number and volume of lesions in patients at risk of multiple sclerosis (MS) after a first clinical demyelinating event, a study based on Phase 3 trial…read more
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) forum was held virtually in February this year. The Neurology Research Review have selected and reviewed 10 presentations.read more
Special issue of Neurology Research Review, focusing specifically on MS.read more
Funded by the International Progressive MS Alliance, a first-of-its-kind global research network aims to develop new, effective treatments for progressive MS.read more
The Alliance Drug Discovery Collaborative Research Network led by Professor Francisco Quintana at Harvard’s Brigham and Women’s Hospital has reported that a subset of brain cells (astrocytes) may be directed…read more
Progressive MS Alliance Collaborative Research Network Study Shows that Stem Cells Derived from Skin Cells of People with MS Make Normal Nerve-Insulating Myelin Results Open More Possibilities for Myelin Repairread more
The MBIE Science Whitinga Fellowship is aimed at supporting excellent early career researchers impacted by COVID-19 in the New Zealand research science system. This is a one-off initiative and will…read more
A recent scientific publication has been touted as highlighting a potential vaccine for MS by some media outlets. So, what does this mean? And how does this tie in with…read more
The projects cover a wide range of topics and research areas, including research into COVID-19 in people with MS in Australia.read more
This article, written by the Journal of Multiple Sclerosis and related disorders, (MSARD) includes data from clinical trials, post marketing safety surveillance and a US electronic medical records database, Optum.read more
These webinars cover the latest in MS research. Highlights include Dr Wallace Brownlee, who dialled in from London to update us on HSCT treatments for MS, and Justin O’Sullivan speaking…read more
New data on the long term benefits of Ocrelizumab for PPMS has recently been published 29 October 2020 on the Lancet Ocrelizumab is currently funded for RRMS in New Zealand…read more
Note: This article was originally published on www.multiplesclerosisnewstoday.com, written by Marta Figueiredo and fact checked by Patrícia Silva, PHD. MD1003, MedDay Pharmaceuticals’ high-dose biotin therapy, failed to significantly improve functional…read more
A survey exploring participants’ perspectives of people living with Multiple Sclerosis to better understand adjustment to diagnosis and the role of psychological support in the patient journey.read more
Keep up with the latest researching on COVID-19 as it relates to Multiple Sclerosisread more
Exploring patterns of medicinal cannabis use prior to implementation of the new Medicinal Cannabis Scheme (MCS) in New Zealand.read more
Karen Oldfield is a Doctoral student in Clinical Research at Victoria University of Wellington and Medical Research Fellow at the Medical Research Institute of New Zealand. Her PhD is exploring…read more